;PMID: 7704243
;source_file_794.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..32] = [t:0..32]
;1)sentence:[e:37..115] = [t:37..115]
;2)section:[e:119..187] = [t:119..187]
;3)section:[e:191..277] = [t:191..277]
;4)sentence:[e:281..579] = [t:281..579]
;5)sentence:[e:580..847] = [t:580..847]
;6)sentence:[e:848..938] = [t:848..938]
;7)sentence:[e:939..1077] = [t:939..1077]
;8)sentence:[e:1078..1265] = [t:1078..1265]
;9)sentence:[e:1266..1444] = [t:1266..1444]
;10)sentence:[e:1445..1659] = [t:1445..1659]
;11)section:[e:1663..1707] = [t:1663..1707]

;section 0 Span:0..32
;Pathol Int  1995 Jan;45(1):45-50
(SEC
  (FRAG (IN:[0..6] Pathol) (NNP:[7..10] Int) (CD:[12..16] 1995)
        (.:[17..24] Jan;45-LRB-) (CD:[24..25] 1) (-RRB-:[25..26] -RRB-)
        (CD:[26..29] :45) (::[29..30] -) (CD:[30..32] 50)))

;sentence 1 Span:37..115
;N-ras mutation of thyroid tumor with special reference to the follicular
;type.
;[37..42]:gene-rna:"N-ras"
;[55..114]:malignancy:"thyroid tumor with special reference to the follicular
;type"
(SENT
  (NP-HLN
    (NP (NN:[37..42] N-ras) (NN:[43..51] mutation))
    (PP (IN:[52..54] of)
      (NP (JJ:[55..62] thyroid) (NN:[63..68] tumor)))
    (PP (IN:[69..73] with)
      (NP
        (NP (JJ:[74..81] special) (NN:[82..91] reference))
        (PP (TO:[92..94] to)
          (NP (DT:[95..98] the) (JJ:[99..109] follicular) (NN:[110..114] type)))))
    (.:[114..115] .)))

;section 2 Span:119..187
;Oyama T, Suzuki T, Hara F, Iino Y, Ishida T, Sakamoto A, Nakajima T.
(SEC
  (FRAG (NNP:[119..124] Oyama) (NNP:[125..126] T) (,:[126..127] ,)
        (NNP:[128..134] Suzuki) (NNP:[135..136] T) (,:[136..137] ,)
        (NNP:[138..142] Hara) (NNP:[143..144] F) (,:[144..145] ,)
        (NNP:[146..150] Iino) (NNP:[151..152] Y) (,:[152..153] ,)
        (NNP:[154..160] Ishida) (NNP:[161..162] T) (,:[162..163] ,)
        (NNP:[164..172] Sakamoto) (NNP:[173..174] A) (,:[174..175] ,)
        (NNP:[176..184] Nakajima) (NNP:[185..187] T.)))

;section 3 Span:191..277
;Second Department of Pathology, Gunma University School of Medicine,
;Maebashi,  Japan.
(SEC
  (FRAG (NNP:[191..197] Second) (NNP:[198..208] Department) (IN:[209..211] of)
        (NNP:[212..221] Pathology) (,:[221..222] ,) (NNP:[223..228] Gunma)
        (NNP:[229..239] University) (NNP:[240..246] School) (IN:[247..249] of)
        (NNP:[250..258] Medicine) (,:[258..259] ,) (NNP:[260..268] Maebashi)
        (,:[268..269] ,) (NNP:[271..276] Japan) (.:[276..277] .)))

;sentence 4 Span:281..579
;Using the method of polymerase chain reaction-single strand conformation 
;polymorphism, the point mutations of the ras oncogenes in a total of 33
;thyroid  tissues, including 12 follicular adenomas, 6 follicular carcinomas,
;11 papillary  carcinomas, and 4 undifferentiated carcinomas, were examined.
;[301..311]:gene-protein:"polymerase"
;[373..388]:variation-type:"point mutations"
;[396..399]:gene-rna:"ras"
;[458..477]:malignancy:"follicular adenomas"
;[481..502]:malignancy:"follicular carcinomas"
;[507..528]:malignancy:"papillary  carcinomas"
;[536..563]:malignancy:"undifferentiated carcinomas"
(SENT
  (S
    (S-MNR
      (NP-SBJ (-NONE-:[281..281] *))
      (VP (VBG:[281..286] Using)
        (NP
          (NP (DT:[287..290] the) (NN:[291..297] method))
          (PP (IN:[298..300] of)
            (NP
              (NML (NN:[301..311] polymerase) (NN:[312..317] chain)
                   (NN:[318..326] reaction))
              (HYPH:[326..327] -)
              (NML (JJ:[327..333] single) (NN:[334..340] strand))
              (NN:[341..353] conformation) (NN:[355..367] polymorphism))))))
    (,:[367..368] ,)
    (NP-SBJ-1
      (NP (DT:[369..372] the)
         (NN:[373..378] point) (NNS:[379..388] mutations))
      (PP (IN:[389..391] of)
        (NP (DT:[392..395] the) (NN:[396..399] ras) (NNS:[400..409] oncogenes)))
      (PP-LOC (IN:[410..412] in)
        (NP
          (NP (DT:[413..414] a) (NN:[415..420] total))
          (PP (IN:[421..423] of)
            (NP
              (NP (CD:[424..426] 33) (JJ:[427..434] thyroid)
                  (NNS:[436..443] tissues))
              (,:[443..444] ,)
              (PP (VBG:[445..454] including)
                (NP
                  (NP (CD:[455..457] 12)
                     (JJ:[458..468] follicular) (NNS:[469..477] adenomas))
                  (,:[477..478] ,)
                  (NP (CD:[479..480] 6)
                     (JJ:[481..491] follicular) (NNS:[492..502] carcinomas))
                  (,:[502..503] ,)
                  (NP (CD:[504..506] 11)
                     (JJ:[507..516] papillary) (NNS:[518..528] carcinomas))
                  (,:[528..529] ,) (CC:[530..533] and)
                  (NP (CD:[534..535] 4)
                     (JJ:[536..552] undifferentiated)
                     (NNS:[553..563] carcinomas)))))))))
    (,:[563..564] ,)
    (VP (VBD:[565..569] were)
      (VP (VBN:[570..578] examined)
        (NP-1 (-NONE-:[578..578] *))))
    (.:[578..579] .)))

;sentence 5 Span:580..847
;The frequency of  the mutation was 3% (1/33) in codon 12, 13 of Ki-ras and
;18% (6/33) in codon 61  of N-ras, including 17% (2/12) in follicular adenoma,
;50% (3/6) in follicular  carcinoma, 0% (0/11) in papillary carcinoma and 25%
;(1/4) in undifferentiated  carcinoma.
;[602..610]:variation-event:"mutation"
;[628..636]:variation-location:"codon 12"
;[628..633]...[638..640]:variation-location:"codon"..."13"
;[644..650]:gene-rna:"Ki-ras"
;[669..677]:variation-location:"codon 61"
;[682..687]:gene-rna:"N-ras"
;[713..731]:malignancy:"follicular adenoma"
;[746..767]:malignancy:"follicular  carcinoma"
;[782..801]:malignancy:"papillary carcinoma"
;[819..846]:malignancy:"undifferentiated  carcinoma"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[580..583] The) (NN:[584..593] frequency))
      (PP (IN:[594..596] of)
        (NP (DT:[598..601] the) (NN:[602..610] mutation))))
    (VP
      (VP (VBD:[611..614] was)
        (NP-PRD=2 (CD:[615..616] 3) (NN:[616..617] %)
          (PRN (-LRB-:[618..619] -LRB-)
            (NP
              (NP (CD:[619..620] 1))
              (PP (SYM:[620..621] /)
                (NP (CD:[621..623] 33))))
            (-RRB-:[623..624] -RRB-)))
        (PP-LOC=3 (IN:[625..627] in)
          (NP
            (NP
              (NP
                (NML-1 (NN:[628..633] codon))
                (CD:[634..636] 12))
              (,:[636..637] ,)
              (NP
                (NML-1 (-NONE-:[637..637] *P*))
                (CD:[638..640] 13)))
            (PP (IN:[641..643] of)
              (NP (NN:[644..650] Ki-ras))))))
      (CC:[651..654] and)
      (VP
        (NP-PRD=2 (CD:[655..657] 18) (NN:[657..658] %)
          (PRN (-LRB-:[659..660] -LRB-)
            (NP
              (NP (CD:[660..661] 6))
              (PP (SYM:[661..662] /)
                (NP (CD:[662..664] 33))))
            (-RRB-:[664..665] -RRB-)))
        (PP-LOC=3 (IN:[666..668] in)
          (NP
            (NP (NN:[669..674] codon) (CD:[675..677] 61))
            (PP (IN:[679..681] of)
              (NP (NN:[682..687] N-ras))))))
      (,:[687..688] ,)
      (PP (VBG:[689..698] including)
        (NP
          (NP
            (NP (CD:[699..701] 17) (NN:[701..702] %)
              (PRN (-LRB-:[703..704] -LRB-)
                (NP
                  (NP (CD:[704..705] 2))
                  (PP (SYM:[705..706] /)
                    (NP (CD:[706..708] 12))))
                (-RRB-:[708..709] -RRB-)))
            (PP-LOC (IN:[710..712] in)
              (NP (JJ:[713..723] follicular) (NN:[724..731] adenoma))))
          (,:[731..732] ,)
          (NP
            (NP (CD:[733..735] 50) (NN:[735..736] %)
              (PRN (-LRB-:[737..738] -LRB-)
                (NP
                  (NP (CD:[738..739] 3))
                  (PP (SYM:[739..740] /)
                    (NP (CD:[740..741] 6))))
                (-RRB-:[741..742] -RRB-)))
            (PP-LOC (IN:[743..745] in)
              (NP (JJ:[746..756] follicular) (NN:[758..767] carcinoma))))
          (,:[767..768] ,)
          (NP
            (NP
              (NP (CD:[769..770] 0) (NN:[770..771] %)
                (PRN (-LRB-:[772..773] -LRB-)
                  (NP
                    (NP (CD:[773..774] 0))
                    (PP (SYM:[774..775] /)
                      (NP (CD:[775..777] 11))))
                  (-RRB-:[777..778] -RRB-)))
              (PP-LOC (IN:[779..781] in)
                (NP (JJ:[782..791] papillary) (NN:[792..801] carcinoma))))
            (CC:[802..805] and)
            (NP
              (NP (CD:[806..808] 25) (NN:[808..809] %)
                (PRN (-LRB-:[810..811] -LRB-)
                  (NP
                    (NP (CD:[811..812] 1))
                    (PP (SYM:[812..813] /)
                      (NP (CD:[813..814] 4))))
                  (-RRB-:[814..815] -RRB-)))
              (PP-LOC (IN:[816..818] in)
                (NP (JJ:[819..835] undifferentiated) (NN:[837..846] carcinoma))))))))
    (.:[846..847] .)))

;sentence 6 Span:848..938
;In follicular adenoma, positivity was observed in microfollicular or 
;trabecular subtypes.
;[851..869]:malignancy:"follicular adenoma"
;[898..913]:malignancy:"microfollicular"
;[918..937]:malignancy:"trabecular subtypes"
(SENT
  (S
    (PP-LOC (IN:[848..850] In)
      (NP (JJ:[851..861] follicular) (NN:[862..869] adenoma)))
    (,:[869..870] ,)
    (NP-SBJ-1 (NN:[871..881] positivity))
    (VP (VBD:[882..885] was)
      (VP (VBN:[886..894] observed)
        (NP-1 (-NONE-:[894..894] *))
        (PP-LOC (IN:[895..897] in)
          (NP
            (ADJP (JJ:[898..913] microfollicular) (CC:[914..916] or)
                  (JJ:[918..928] trabecular))
            (NNS:[929..937] subtypes)))))
    (.:[937..938] .)))

;sentence 7 Span:939..1077
;Furthermore, the mutation of ras, was examined in  histologically different
;parts, coexisting in the same tumor in a total of four  cases.
;[968..971]:gene-rna:"ras"
;[1045..1050]:malignancy:"tumor"
(SENT
  (S
    (ADVP (RB:[939..950] Furthermore))
    (,:[950..951] ,)
    (NP-SBJ-1
      (NP (DT:[952..955] the) (NN:[956..964] mutation))
      (PP (IN:[965..967] of)
        (NP (NN:[968..971] ras))))
    (,:[971..972] ,)
    (VP (VBD:[973..976] was)
      (VP (VBN:[977..985] examined)
        (NP-1 (-NONE-:[985..985] *))
        (PP-LOC (IN:[986..988] in)
          (NP
            (ADJP (RB:[990..1004] histologically) (JJ:[1005..1014] different))
            (NNS:[1015..1020] parts)))
        (,:[1020..1021] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1021..1021] *))
          (VP (VBG:[1022..1032] coexisting)
            (PP-LOC (IN:[1033..1035] in)
              (NP (DT:[1036..1039] the) (JJ:[1040..1044] same)
                  (NN:[1045..1050] tumor)))
            (PP (IN:[1051..1053] in)
              (NP
                (NP (DT:[1054..1055] a) (NN:[1056..1061] total))
                (PP (IN:[1062..1064] of)
                  (NP (CD:[1065..1069] four) (NNS:[1071..1076] cases)))))))))
    (.:[1076..1077] .)))

;sentence 8 Span:1078..1265
;Both the undifferentiated carcinoma and coexisting follicular adenoma,  and
;both the microfollicular adenoma and trabecular nodule growing in the tumor, 
;had the same N-ras (61) mutation.
;[1087..1113]:malignancy:"undifferentiated carcinoma"
;[1129..1147]:malignancy:"follicular adenoma"
;[1163..1186]:malignancy:"microfollicular adenoma"
;[1191..1229]:malignancy:"trabecular nodule growing in the tumor"
;[1245..1250]:gene-rna:"N-ras"
;[1252..1254]:variation-location:"61"
;[1256..1264]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ
      (NP (CC:[1078..1082] Both) (DT:[1083..1086] the)
        (NML
          (NML (JJ:[1087..1103] undifferentiated) (NN:[1104..1113] carcinoma))
          (CC:[1114..1117] and)
          (NML (VBG:[1118..1128] coexisting)
             (JJ:[1129..1139] follicular) (NN:[1140..1147] adenoma))))
      (,:[1147..1148] ,) (CC:[1150..1153] and)
      (NP (CC:[1154..1158] both)
        (NP (DT:[1159..1162] the)
          (NML
            (NML (JJ:[1163..1178] microfollicular) (NN:[1179..1186] adenoma))
            (CC:[1187..1190] and)
            (NML
              (NML (JJ:[1191..1201] trabecular) (NN:[1202..1208] nodule))
              (VP (VBG:[1209..1216] growing)
                (PP-LOC (IN:[1217..1219] in)
                  (NP (DT:[1220..1223] the) (NN:[1224..1229] tumor)))))))))
    (,:[1229..1230] ,)
    (VP (VBD:[1232..1235] had)
      (NP (DT:[1236..1239] the) (JJ:[1240..1244] same)
        (NML (NN:[1245..1250] N-ras)
          (PRN (-LRB-:[1251..1252] -LRB-)
            (NP (CD:[1252..1254] 61))
            (-RRB-:[1254..1255] -RRB-)))
        (NN:[1256..1264] mutation)))
    (.:[1264..1265] .)))

;sentence 9 Span:1266..1444
;Direct sequencing analysis showed that all  mutations were CAA (Gln) to CGA
;(Arg) transition of codon 61, except for CAA to  AAA transversion in one case
;of follicular carcinoma.
;[1310..1319]:variation-event:"mutations"
;[1325..1328]:variation-state-original:"CAA"
;[1330..1333]:variation-state-original:"Gln"
;[1338..1341]:variation-state-altered:"CGA"
;[1343..1346]:variation-state-altered:"Arg"
;[1348..1358]:variation-type:"transition"
;[1362..1370]:variation-location:"codon 61"
;[1383..1386]:variation-state-original:"CAA"
;[1391..1394]:variation-state-altered:"AAA"
;[1395..1407]:variation-type:"transversion"
;[1423..1443]:malignancy:"follicular carcinoma"
(SENT
  (S
    (NP-SBJ
      (NML (JJ:[1266..1272] Direct) (NN:[1273..1283] sequencing))
      (NN:[1284..1292] analysis))
    (VP (VBD:[1293..1299] showed)
      (SBAR (IN:[1300..1304] that)
        (S
          (NP-SBJ (DT:[1305..1308] all) (NNS:[1310..1319] mutations))
          (VP (VBD:[1320..1324] were)
            (NP-PRD
              (NP
                (NML
                  (NML
                    (NML (NN:[1325..1328] CAA))
                    (NML (-LRB-:[1329..1330] -LRB-) (NN:[1330..1333] Gln)
                         (-RRB-:[1333..1334] -RRB-)))
                  (PP (TO:[1335..1337] to)
                    (NP
                      (NP (NN:[1338..1341] CGA))
                      (NP (-LRB-:[1342..1343] -LRB-) (NN:[1343..1346] Arg)
                          (-RRB-:[1346..1347] -RRB-)))))
                (NN:[1348..1358] transition))
              (PP (IN:[1359..1361] of)
                (NP (NN:[1362..1367] codon) (CD:[1368..1370] 61))))
            (,:[1370..1371] ,)
            (PP (IN:[1372..1378] except)
              (PP (IN:[1379..1382] for)
                (NP
                  (NP
                    (NML
                      (NML (NN:[1383..1386] CAA))
                      (PP (TO:[1387..1389] to)
                        (NP (NN:[1391..1394] AAA))))
                    (NN:[1395..1407] transversion))
                  (PP (IN:[1408..1410] in)
                    (NP
                      (NP (CD:[1411..1414] one) (NN:[1415..1419] case))
                      (PP (IN:[1420..1422] of)
                        (NP (JJ:[1423..1433] follicular)
                            (NN:[1434..1443] carcinoma))))))))))))
    (.:[1443..1444] .)))

;sentence 10 Span:1445..1659
;A similar genetic  abnormality of N-ras genes at codon 61 between follicular
;adenoma and follicular  carcinoma suggests that the mutation of N-ras at
;codon 61 might play a part in  oncogenesis in follicular tumors.
;[1455..1475]:variation-event:"genetic  abnormality"
;[1479..1484]:gene-rna:"N-ras"
;[1494..1502]:variation-location:"codon 61"
;[1511..1529]:malignancy:"follicular adenoma"
;[1534..1555]:malignancy:"follicular  carcinoma"
;[1574..1582]:variation-event:"mutation"
;[1586..1591]:gene-rna:"N-ras"
;[1595..1603]:variation-location:"codon 61"
;[1641..1658]:malignancy:"follicular tumors"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1445..1446] A) (JJ:[1447..1454] similar)
         (JJ:[1455..1462] genetic) (NN:[1464..1475] abnormality))
      (PP (IN:[1476..1478] of)
        (NP (NN:[1479..1484] N-ras) (NNS:[1485..1490] genes)))
      (PP-LOC (IN:[1491..1493] at)
        (NP (NN:[1494..1499] codon) (CD:[1500..1502] 61)))
      (PP (IN:[1503..1510] between)
        (NP
          (NP (JJ:[1511..1521] follicular) (NN:[1522..1529] adenoma))
          (CC:[1530..1533] and)
          (NP (JJ:[1534..1544] follicular) (NN:[1546..1555] carcinoma)))))
    (VP (VBZ:[1556..1564] suggests)
      (SBAR (IN:[1565..1569] that)
        (S
          (NP-SBJ
            (NP (DT:[1570..1573] the) (NN:[1574..1582] mutation))
            (PP (IN:[1583..1585] of)
              (NP (NN:[1586..1591] N-ras)))
            (PP-LOC (IN:[1592..1594] at)
              (NP (NN:[1595..1600] codon) (CD:[1601..1603] 61))))
          (VP (MD:[1604..1609] might)
            (VP (VB:[1610..1614] play)
              (NP (DT:[1615..1616] a) (NN:[1617..1621] part))
              (PP (IN:[1622..1624] in)
                (NP (NN:[1626..1637] oncogenesis)))
              (PP-LOC (IN:[1638..1640] in)
                (NP (JJ:[1641..1651] follicular) (NNS:[1652..1658] tumors))))))))
    (.:[1658..1659] .)))

;section 11 Span:1663..1707
;PMID: 7704243 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1663..1667] PMID) (::[1667..1668] :) (CD:[1669..1676] 7704243)
        (NN:[1677..1678] -LSB-) (NNP:[1678..1684] PubMed) (::[1685..1686] -)
        (NN:[1687..1694] indexed) (IN:[1695..1698] for)
        (NNP:[1699..1707] MEDLINE-RSB-)))
